

# FOR IMMEDIATE RELEASE

# AMERICAN VANGUARD REPORTS FOURTH QUARTER & FULL YEAR 2016 RESULTS Full-Year Revenues Increase 8% and Earnings Grow 94%

Newport Beach, CA – March 6, 2017 – American Vanguard Corporation (NYSE:AVD) today announced financial results for the fourth quarter and full year ended December 31, 2016.

Fiscal 2016 Fourth Quarter Financial Highlights – versus Fiscal 2015 Fourth Quarter:

- Net sales were \$87.5 million in Q4 2016 compared to \$83.8 million in Q4 2015.
- Net income was \$3.9 million in Q4 2016 compared to \$3.0 million in Q4 2015.
- Earnings per diluted share were \$0.13 in Q4 2016 compared to \$0.10 in Q4 2015.

# Fiscal 2016 Financial Highlights - versus Fiscal 2015:

- Net sales were \$312.1 million in FY 2016 compared to \$289.4 million in FY 2015.
- Net income was \$12.8 million in FY 2016 compared to \$6.6 million in FY 2015.
- Earnings per diluted share were \$0.44 in FY 2016 compared to \$0.23 in FY 2015.

Eric Wintemute, Chairman and CEO of American Vanguard, stated: "Our improved performance in 2016 reflects a solid base business and disciplined management in spite of industry conditions, as low crop commodity prices continue to cause cautious purchasing of all crop inputs, including crop protection products. In 2016 our industry posted revenues that, on average, were about 7% below those of the prior year. In contrast, by following a practice of systematically reducing inventory to meet true demand, maintaining brand value, and optimizing our cost structures, this past year American Vanguard has been able to generate a sequential revenue increase of 8% and earnings growth of 94%."

Mr. Wintemute continued: "We continue to see stable demand for many of our products both at home and abroad. Revenue growth in 2016 was driven mainly by our herbicide products and by our valuable noncrop portfolio. In addition, we have expanded domestic market access with our YES-Retail program and have promoted several new products in international regions and the US soybean market. Further, our operations team has continued to control manufacturing costs, and we have exceeded our inventory reduction target with a year-end level of \$121 million. Improved sales, operating earnings and working capital management have enabled us to generate \$125 million in cash over the last 2 years. Our improved cash flow has allowed us to reduce our debt to \$41 million, increased our borrowing capacity and, as a result, positioned the Company for product acquisitions that we expect will likely emerge from the current round of industry consolidation."

Mr. Wintemute concluded: "Our outlook for 2017 is positive. We anticipate a long planting season this Spring, following relatively temperate winter weather conditions, that often stimulate heavier pest pressure. We expect relative stability in the Midwest corn markets; this should drive sales of our corn soil insecticides and herbicides, given that channel inventory levels are now at close to historically normal levels. An expected 10% increase in U.S. cotton acreage favors our foliar insecticide and harvest aid

products. Internationally, we are poised for modest growth driven by the market penetration of several newly acquired products. In our non-crop business, we also expect to experience continued expansion. We will, of course, continue to manage working capital and operational costs closely. However, given the shift to precision agriculture, it is important that we continue to invest in technology innovation, such as SIMPAS, as we did in 2016. Finally, we will continue to expand our international footprint through product acquisitions and strategic alliances such as our Hong Kong joint venture. In short, we will continue to do the things that have enabled us to improve our financial performance and balance sheet, while positioning ourselves for the future."

# **Conference Call**

Eric Wintemute, Chairman & CEO, Bob Trogele, EVP & COO and David T. Johnson, VP & CFO, will conduct a conference call from our manufacturing facility in Axis, Alabama...focusing on the financial results and strategic themes at 9:00 am ET on Tuesday, March 7, 2017. Interested parties may participate in the call by dialing (201) 493-6744. Please call in 10 minutes before the call is scheduled to begin, and ask for the American Vanguard call. The conference call will also be webcast live via the News and Media section of the Company's web site at www.american-vanguard.com. To listen to the live webcast, go to the web site at least 15 minutes early to register, download and install any necessary audio software. If you are unable to listen live, the conference call will be archived on the Company's web site.

### About American Vanguard

American Vanguard Corporation is a diversified specialty and agricultural products company that develops and markets products for crop protection and management, turf and ornamentals management and public and animal health. American Vanguard is included on the Russell 2000® and Russell 3000® Indexes and the Standard & Poor's Small Cap 600 Index. To learn more about American Vanguard, please reference the Company's web site at www.american-vanguard.com.

The Company, from time to time, may discuss forward-looking information. Except for the historical information contained in this release, all forward-looking statements are estimates by the Company's management and are subject to various risks and uncertainties that may cause results to differ from management's current expectations. Such factors include weather conditions, changes in regulatory policy and other risks as detailed from time-to-time in the Company's SEC reports and filings. All forward-looking statements, if any, in this release represent the Company's judgment as of the date of this release.

Company Contact: American Vanguard Corporation William A. Kuser, Director of Investor Relations (949) 260-1200 williamk@amvac-chemical.com Investor Representative The Equity Group Inc. www.theequitygroup.com Lena Cati Lcati@equityny.com (212) 836-9611

### CONSOLIDATED BALANCE SHEETS December 31, 2016 and 2015 (In thousands, except share data)

		2016		2015	
Assets					
Current assets:					
Cash and cash equivalents	\$	7,869	\$	5,524	
Receivables:					
Trade, net of allowance for doubtful accounts of \$42 and \$423,					
respectively		83,777		72,835	
Other		3,429		2,554	
		87,206		75,389	
Inventories		120,576		136,477	
Prepaid expenses		11,424		11,172	
Total current assets		227,075		228,562	
Property, plant and equipment, net		50,295		47,972	
Intangible assets, net of applicable amortization		121,433		129,160	
Other assets	- <u></u>	31,153	- <u></u>	29,576	
Total assets	\$	429,956	\$	435,270	
Liabilities and Stockholders' Equity					
Current liabilities:					
Current installments of other notes payable	\$		\$	55	
Current installments of other liabilities		26		514	
Accounts payable		24,358		15,343	
Deferred revenue		3,848		8,888	
Accrued program costs		42,930		44,371	
Accrued expenses and other payables		12,072		7,111	
Income taxes payable		13,840		12,430	
Total current liabilities		97,074		88,712	
Long-term debt and other notes payable, excluding current installments		40,951		68,321	
Other liabilities, excluding current installments		2,868		3,054	
Deferred income tax liabilities, net		6,706		6,857	
Total liabilities		147,599		166,944	
Commitments and contingent liabilities					
Stockholders' equity:					
Preferred stock, \$.10 par value per share; authorized 400,000 shares;					
none issued		—			
Common stock, \$.10 par value per share; authorized 40,000,000					
shares; issued 31,819,695 shares in 2016 and 31,638,225 shares in		2 1 0 2		2.1.64	
2015		3,183		3,164	
Additional paid-in capital		71,699		68,534	
Accumulated other comprehensive loss		(4,851)		(3,541)	
Retained earnings		220,428		208,507	
		290,459		276,664	
Less treasury stock at cost, 2,450,634 shares in 2016 and in 2015		(8,269)		(8,269)	
American Vanguard Corporation stockholders' equity		282,190		268,395	
Non-controlling interest		167		(69)	
Total stockholders' equity	<u>_</u>	282,357	<i>d</i> +	268,326	
Total liabilities and stockholders' equity	\$	429,956	\$	435,270	

#### CONSOLIDATED STATEMENTS OF OPERATIONS Years ended December 31, 2016, 2015 and 2014 (In thousands, except per share data)

	2016		2015	 2014
Net sales	\$ 312,113	\$	289,382	\$ 298,634
Cost of sales	183,825		177,480	 184,138
Gross profit	128,288		111,902	114,496
Operating expenses	 107,748		100,378	 107,786
Operating income	20,540		11,524	6,710
Interest expense, net	1,623		2,562	 3,066
Income before provision for income taxes and loss on equity				
investment	18,917		8,962	3,644
Income taxes expense (benefit)	5,540		2,009	(451)
Income before loss on equity investment	13,377		6,953	4,095
Less net loss from equity method investment	(353)		(636)	(29)
Net income	13,024		6,317	4,066
Net (income) loss attributable to non-controlling interest	(236)		274	775
Net income attributable to American Vanguard	\$ 12,788	\$	6,591	\$ 4,841
Earnings per common share—basic	\$ 0.44	\$	0.23	\$ 0.17
Earnings per common share—assuming dilution	\$ 0.44	\$	0.23	\$ 0.17
Weighted average shares outstanding-basic	28,859		28,673	28,436
Weighted average shares outstanding—assuming dilution	29,394	_	29,237	 28,912

#### ANALYSIS OF SALES Years ended December 31, 2016, 2015 and 2014 (In thousands)

	2016	2015	2014
Net sales:			
Insecticides	\$ 119,226 \$	117,180 \$	135,705
Herbicides/soil fumigants/fungicides	123,540	111,897	101,785
Other, including plant growth regulators	29,438	29,013	30,220
Total crop	272,204	258,090	267,710
Non-crop	39,909	31,292	30,924
	\$ 312,113 \$	289,382 \$	298,634
Net sales:			
U.S.	\$ 228,854 \$	212,087 \$	224,928
International	83,259	77,295	73,706
Net sales:	\$ 312,113 \$	289,382 \$	289,634

### CONSOLIDATED STATEMENTS OF CASH FLOWS Years ended December 31, 2016, 2015 and 2014 (In thousands)

	 2016	 2015		2014
Increase cash				
Cash flows from operating activities:				
Net income	\$ 13,024	\$ 6,317	\$	4,066
Adjustments to reconcile net income to net cash provided by (used in)				
operating activities:	16 207	1 < 474		16 000
Depreciation and amortization of fixed and intangible assets	16,327	16,474		16,332
Amortization of other long term assets	5,203	5,275		5,811
Amortization of discounted liabilities	16	140		324
Stock-based compensation	3,167	3,881		4,153
Excess tax benefit from share based compensation Increase in deferred income taxes	(96)	(23)		(300)
	(151)	27		2,619 983
Operating loss from equity method investment	353	629		
Loss (gain) from dilution of equity method investment		7		(954)
Changes in assets and liabilities associated with operations:	(11.017)	12 024		(12 471)
(Increase) decrease in net receivables Decrease (increase) in inventories	(11,817) 12,373	13,034 29,154		(13,471) (25,801)
Increase in income tax receivable/payable, net	12,373	4,872		4,424
(Increase) decrease in prepaid expenses and other assets	(344)	2,082		(4,743)
Increase (decrease) in accounts payable	9,015	(5,068)		(19,951)
(Decrease) increase in deferred revenue	(5,040)	7,990		(19,931) (2,890)
Increase (decrease) in other payables, accrued program costs and	(3,040)	7,770		(2,0)0)
expenses	3,190	(6,223)		(4,697)
Net cash provided by (used in) operating activities	46,406	78,568		(34,095)
Cash flows from investing activities:	10,100	10,200		(31,0)3)
Capital expenditures	(10,630)	(6,899)		(7,180)
Investment	(3,283)	(125)		(500)
Acquisitions of intangible assets	(224)	(36,667)		(200)
Net cash used in investing activities	 (14,137)	 (43,691)	-	(7,680)
Cash flows from financing activities:	 (11,107)	 (10,0)1)		(1,000)
Payments under line of credit agreement	(107,600)	(121,400)		(44,600)
Borrowings under line of credit agreement	80,000	90,880		92,450
Payment on other long-term liabilities	(704)	(1,543)		(1,756)
Excess tax benefit from share based compensation	96	23		300
Repurchases of common stock	_	_		(1,531)
Proceeds from the issuance of common stock (sale of stock under ESPP				( , ,
and exercise of stock options)	241	317		1,666
Non-controlling interest contribution	_			299
Payment of cash dividends	 (578)	 (1,141)	_	(5,672)
Net cash (used in) provided by financing activities	 (28,545)	(32,864)		41,156
Net increase (decrease) in cash and cash equivalents	 3,724	2,013		(619)
Effect of exchange rate changes on cash	(1,379)	(1,374)		(1,176)
Cash and cash equivalents at beginning of year	 5,524	 4,885	_	6,680
Cash and cash equivalents at end of year	\$ 7,869	\$ 5,524	\$	4,885
Supplemental cash flow information:		 		
Cash paid (received) during the year for:				
Interest	\$ 1,748	\$ 2,750	\$	2,298
Income taxes, net	\$ 4,947	\$ (3,697)	\$	(8,206)